Although there are some adverse effects of Ber in clinic monotherapy for hyperlipidemia and diabetes, some studies revealed that multidrug resistance of Ber may occur in a long-term single administration because of Ber being the substrate for p-glycoprotein, which resulted in a decrease of its efficacy in LDLR regulation [9,22,23]. Here, ABCB1 is linked to diabetes mellitus.